Corrigendum to "Downregulation of Thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer" [Redox Biol. 34 (2020) 101528]

Affiliations

• ¹ Institute of Biomedicine of Seville (IBiS), Hospital University "Virgen Del Rocío"/CSIC/University of Seville, Seville, Spain; Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd), Madrid, Spain.
• ² Institute of Biomedicine of Seville (IBiS), Hospital University "Virgen Del Rocío"/CSIC/University of Seville, Seville, Spain.
• ³ Bruker BioSpin Corporation, Billerica, MA, USA.
• ⁴ Université Côte D'Azur, CNRS, Inserm, iBV, Nice, France.
• ⁵ Research Unit, Hospital University "Santa Cristina", Health Research Institute "La Princesa" (IIS-IP), Madrid, Spain; Biomedical Research Network Center for Cardiovascular Diseases (CIBERCV), Madrid, Spain.
• ⁶ Department of Physiology, Faculty of Pharmacy, University of Valencia. Burjassot, Valencia, Spain.
• ⁷ Department of Biochemistry and Molecular Biology, University of Cordoba, Cordoba, Spain; Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Cordoba, Spain.
• ⁸ Institute of Biomedicine of Seville (IBiS), Hospital University "Virgen Del Rocío"/CSIC/University of Seville, Seville, Spain; Department of General Surgery, Hospital University "Virgen del Rocío"/IBiS/CSIC/University of Seville, Seville, Spain; Biomedical Research Network Center for Liver and Digestive Diseases (CIBERehd), Madrid, Spain. Electronic address: [email protected].